Verona Pharma Completes Enrollment in ENHANCE-1 48-week Subset

ENHANCE-2 Screening Complete with Full Enrollment Expected in January 2022

ENHANCE Phase 3 Program on Track to Report Top-line Data in 2022

LONDON and RALEIGH, N.C., Jan. 05, 2022 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces enrollment completed in the 48-week subset of the ENHANCE-1 trial in December 2021. The ENHANCE-2 trial has completed screening with 788 subjects randomized as of January 4, 2022, and full enrollment is expected by the end of January 2022. The Phase 3 ENHANCE (“Ensifentrine as a Novel inHAled Nebulized COPD thErapy”) program is evaluating nebulized ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease (“COPD”).

Read more…


By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...